Sign In
Buy INSM
$106.92
-0.490 (-0.456%)
At Close: Jul 24, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
10:00am, Thursday, 01'st Jan 2026
NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to co
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
12:37pm, Tuesday, 30'th Dec 2025
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM). Such investors ar
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm
09:29pm, Monday, 29'th Dec 2025
LOS ANGELES--(BUSINESS WIRE)---- $INSM--INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm.
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
03:35am, Friday, 26'th Dec 2025
Mineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
11:56am, Wednesday, 24'th Dec 2025
MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.
Nike, Insmed, And Arm Are Among Top 10 Large Cap Losers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?
10:01am, Sunday, 21'st Dec 2025
Last week's biggest large-cap laggards were Nike, Arm, and Lennar, sliding on weak China demand, analyst downgrades, earnings/CFO headlines, and broader crypto/energy pressure.
Assenagon Asset Management S.A. Grows Position in Insmed, Inc. $INSM
04:36am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. lifted its holdings in Insmed, Inc. (NASDAQ: INSM) by 76.1% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securitie
Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news
06:09pm, Thursday, 18'th Dec 2025
Mizuho's Jared Holz joins 'Fast Money' to talk Insmed shares tanking on discontinuing development of sinus drug.
Why Is Insmed Stock Falling Thursday?
12:30pm, Thursday, 18'th Dec 2025
Insmed Incorporated (NASDAQ: INSM) stock plunged on Thursday.
INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset
09:01am, Thursday, 18'th Dec 2025
Insmed sinks nearly 20% after Brinsupri failed a phase IIb sinus study, while the company adds a new monoclonal antibody asset to expand its pipeline.
Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
08:04am, Thursday, 18'th Dec 2025
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday.
Insmed Stock Plummets 19%. This Is What Sparked the Selloff.
07:12am, Thursday, 18'th Dec 2025
The biopharmaceutical company said it was discontinuing development of a drug treating a chronic sinus condition.
The 'Worst-Case Scenario' — Why Insmed Just Reversed Its 181% Six-Month Sprint
07:38pm, Wednesday, 17'th Dec 2025
Insmed stock crumbled late Wednesday after the highly rated biotech company scrapped one of its brensocatib studies.
Insmed scraps development of sinus drug after mid-stage study failure
05:35pm, Wednesday, 17'th Dec 2025
Insmed said on Wednesday it had discontinued the development of its experimental anti-inflammatory drug to treat a chronic sinus condition after it failed to show benefit in a mid-stage study, sending
Insmed Provides Clinical and Business Update
04:01pm, Wednesday, 17'th Dec 2025
—Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program— —Company Acquire
